NU7441 (KU-57788): Selective DNA-PK Inhibitor for DNA Repair and Oncology Research

Executive Summary: NU7441 (KU-57788) is an ATP-competitive, small-molecule inhibitor of DNA-dependent protein kinase (DNA-PK) with a reported IC₅₀ of approximately 13–14 nM, demonstrating high specificity and minimal off-target kinase inhibition even at concentrations up to 100 μM (Miao et al., 2023). The compound is insoluble in water and ethanol but dissolves in DMSO at ≥4.13 mg/mL, requiring storage at −20°C to maintain activity (APExBIO product page). NU7441 sensitizes various cancer cell lines, including HeLa and SW620, to DNA-damaging agents such as etoposide and ionizing radiation, leading to cell cycle arrest in G1 phase (Miao et al., 2023). In vivo, intraperitoneal administration at 10 mg/kg, in combination with etoposide phosphate, significantly delays tumor growth in SW620 xenograft models (APExBIO). These characteristics establish NU7441 as a robust tool for dissecting DNA damage response and advancing oncology research.

Biological Rationale

DNA-dependent protein kinase (DNA-PK) is a serine/threonine kinase essential for the nonhomologous end joining (NHEJ) pathway of DNA double-strand break repair. PRKDC encodes the catalytic subunit of DNA-PK, a key node in maintaining genome integrity and regulating cell survival following genotoxic stress (Miao et al., 2023). Dysregulation or overactivity of DNA-PK contributes to tumorigenesis, therapy resistance, and immune evasion in multiple cancer types. Recent studies highlight the PRKDC axis as a mediator of immune escape via PD-L1 phosphorylation and stabilization, underscoring the therapeutic potential of DNA-PK inhibition in oncology (Miao et al., 2023).

Mechanism of Action of NU7441 (KU-57788)

NU7441 functions as a highly selective ATP-competitive inhibitor of DNA-PK. It binds to the kinase domain of DNA-PK, preventing ATP from accessing the catalytic site, thereby blocking phosphorylation events necessary for DNA repair via NHEJ (APExBIO). The compound exhibits an IC₅₀ of 13–14 nM and a K_i of 0.65 nM for DNA-PK. Selectivity profiling demonstrates negligible inhibition of related kinases ATM and ATR at concentrations up to 100 μM, and substantially weaker inhibition of mTOR (IC₅₀ = 1.7 μM) and PI3K (IC₅₀ = 5 μM) (APExBIO). This selectivity ensures minimal interference with parallel signaling pathways, a key requirement for interpretable cellular and in vivo studies.

Evidence & Benchmarks

• NU7441 (KU-57788) demonstrates potent inhibition of DNA-PK activity with an IC₅₀ of 13–14 nM and a K_i of 0.65 nM in biochemical assays (Miao et al., 2023).
• Minimal inhibition of ATM and ATR kinases is observed at concentrations up to 100 μM, confirming high selectivity (APExBIO).
• In HeLa, LoVo, and SW620 cancer cell lines, NU7441 sensitizes cells to etoposide and ionizing radiation, increasing cytotoxicity and inducing G1 cell cycle arrest (Miao et al., 2023).
• In SW620 xenograft mouse models, intraperitoneal dosing of NU7441 at 10 mg/kg with etoposide phosphate doubles the efficacy of etoposide monotherapy, as measured by delayed tumor growth (APExBIO).
• NU7441 is insoluble in water and ethanol but dissolves in DMSO at ≥4.13 mg/mL, facilitating preparation of stock solutions for in vitro and in vivo use (APExBIO).

This article extends prior coverage (NU7441: Selective DNA-PK Inhibitor Redefining DNA Repair) by providing updated benchmarking data and clarifying selectivity limits. It also clarifies workflow guidance compared to (Scenario-Driven Solutions for DNA-PK Inhibitor Use), focusing on integration with DNA damage response assays.

Applications, Limits & Misconceptions

NU7441 (KU-57788) is a robust tool compound for research in DNA repair, cell cycle regulation, and oncology. Inhibition of DNA-PK by NU7441 enables precise dissection of NHEJ-mediated repair and synthetic lethality strategies in combination with DNA-damaging agents. The compound is widely used in cell line models for mechanistic studies, drug sensitization, and cell cycle arrest assays, as well as in xenograft mouse models for preclinical assessment of combination therapies.

However, researchers must consider the following boundaries:

Common Pitfalls or Misconceptions

• NU7441 is not a pan-PI3K family inhibitor; inhibitory activity against mTOR and PI3K is at least 100-fold weaker than for DNA-PK, limiting its use in studies targeting these kinases specifically (APExBIO).
• It does not induce DNA damage directly; its effects are observed only in the presence of DNA-damaging agents or genotoxic stress (Benchmark DNA-PK Inhibitor for DNA Repair).
• NU7441 is insoluble in aqueous buffers and ethanol, requiring dissolution in DMSO for stock preparation (APExBIO).
• Long-term storage of solutions is discouraged due to potential degradation; fresh aliquots are recommended for assay reproducibility (APExBIO).
• Observed phenotypic effects may be cell line– or context-specific, and proper controls are essential for interpretation (Scenario-Driven Solutions).

Workflow Integration & Parameters

NU7441 (KU-57788) is supplied by APExBIO as SKU A8315. For in vitro use, prepare fresh stock solutions in DMSO (≥4.13 mg/mL) and dilute into culture medium for final assay concentrations. Storage at −20°C is recommended, with avoidance of repeated freeze-thaw cycles. In cell-based assays, typical working concentrations range from 10–100 nM for DNA-PK inhibition, with higher doses required for off-target kinase inhibition. In vivo, intraperitoneal dosing at 10 mg/kg in combination with DNA-damaging chemotherapeutics has demonstrated efficacy in xenograft models (APExBIO). For detailed scenario-driven integration, see (Scenario-Driven Solutions for DNA-PK Inhibitor Use), which this article updates with application limits and selectivity clarifications.

Conclusion & Outlook

NU7441 (KU-57788) is an industry benchmark for selective DNA-PK inhibition, enabling precise interrogation of DNA damage response pathways, cell cycle regulation, and therapeutic sensitization in oncology research. Its nanomolar potency and robust selectivity profile minimize off-target effects and enhance experimental reproducibility. The A8315 kit from APExBIO provides researchers with a high-quality reagent for advanced DNA repair studies. Future directions include further elucidation of DNA-PK’s role in tumor immunity and exploration of combinatorial regimens to overcome immune escape and therapeutic resistance (Miao et al., 2023).